13F Pro quality score
Rank #2,737 of 2,777
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from FRACTYL HEALTH, INC.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2024 | 10-K | $93.0K | $-68.7M | — |
| FY 2023 | 10-K | $120.0K | $-77.1M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
FRACTYL HEALTH, INC. (GUTS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GUTS at 10.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,737 of 2,777 stocks — the bottom half of the AI-ranked universe. GUTS scores in the top quartile across institutional flow (86.4). Areas of concern include profitability (0.1) and free cash flow (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.1/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of GUTS by reported 13-F value include Nantahala Capital Management, Catalio Capital Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GUTS trades on the Nasdaq exchange and files with the SEC under CIK 1572616. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GUTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FRACTYL HEALTH, INC. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1572616 →